Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2016-05-13 Earnings Release
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
THR_BUQ12016_NL_FINAL.pdf
Earnings Release Classification · 95% confidence The document is a 'Business Update' for Q1 2016 from ThromboGenics. It provides a detailed overview of the company's R&D pipeline, clinical trial progress (CIRCLE study, TB-403), and business strategy. While it mentions financial figures (cash position), it is not a full quarterly financial report (IR) or an earnings release (ER) focused on financial results; rather, it is a strategic update on operations and development. Given the detailed nature of the content (over 19,000 characters) and its focus on business and clinical progress, it fits best as a Management Report (MDA) detailing business trends and outlook. Q1 2016
2016-05-13 Dutch
THR_BUQ12016_EN Final.pdf
Management Reports Classification · 95% confidence The document is a 'Business Update' for Q1 2016 issued by ThromboGenics. It provides a detailed overview of the company's R&D pipeline, clinical trial progress (CIRCLE study, Oncurious/TB-403), and market access for its drug JETREA. While it contains some financial data (cash and investments), it is primarily a management-led narrative update on business operations and strategy rather than a formal quarterly financial statement or earnings release. It fits the definition of a Management Report (MDA) as it provides management's detailed explanation of business trends, clinical developments, and outlook. Q1 2016
2016-05-13 English
Thrombogenics Second EGM 06062016 ConveningNotice (ENG).pdf
AGM Information Classification · 98% confidence The document is explicitly titled "CONVOCATION OF THE EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING" and details the agenda, quorum requirements, voting procedures, and admission requirements for a meeting scheduled for June 6, 2016. This content directly relates to the formal process of calling and organizing a general shareholders' meeting, which aligns perfectly with the definition of AGM Information (AGM-R). Although it is a convocation notice, it contains the core materials and structure of the meeting itself, making AGM-R more specific than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2016-05-13 English
Thrombogenics Second EGM 06062016 ConveningNotice (NL).pdf
AGM Information Classification · 99% confidence The document is explicitly titled "OPROEPING TOT DE BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS" (Call for the Extraordinary General Meeting of Shareholders). It details the agenda, voting procedures, quorum requirements, and conditions for participation and proxy submission for a meeting scheduled for June 6, 2016. This content directly relates to the organization and materials surrounding a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R). Although it is a call/notice for the meeting, the comprehensive nature of the agenda and procedural details suggests it is the primary material distributed for that specific meeting, rather than just a brief announcement of a report (RPA/RNS).
2016-05-13 Dutch
Annual report - financial information 2015.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT' and covers the financial year 2015. It contains comprehensive sections including a message from the Chairman, management reports, corporate governance, consolidated annual accounts, and the statutory auditor's report. It meets the criteria for a full annual report as it provides detailed financial statements and business analysis for the fiscal year. FY 2015
2016-04-08 English
Jaarverslag - financiële informatie 2015.pdf
Annual Report Classification · 100% confidence The document is titled 'JAARVERSLAG' (Annual Report) for the fiscal year 2015. It contains comprehensive financial statements (consolidated balance sheet, income statement, cash flow), management reports, governance information, and auditor reports. It is clearly the full annual report document, not an announcement or a summary, and meets the criteria for a 10-K equivalent (Annual Report). FY 2015
2016-04-08 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.